Association of host, agent and environment characteristics and the duration of incubation and symptomatic periods of norovirus gastroenteritis

Devasia, Theresa P.; Lopman, Benjamin A.; León, Juan S.; Handel, Andreas

doi:10.1017/s0950268814003288

Cited by 16 publications

(9 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HuNoVs are transmitted by the fecal-oral route causing acute, self-limiting infections typified by vomiting and diarrhea [14][15][16][17]. Considerable quantities of viruses are shed in the feces for several weeks, even after symptoms have resolved [18][19][20][21].…”

Section: Introductionmentioning

confidence: 99%

Vero Cells as a Mammalian Cell Substrate for Human Norovirus

Todd

Tripp

2020

Viruses

View full text Add to dashboard Cite

Human norovirus (HuNoV) is a principal cause of acute gastroenteritis worldwide, particularly in developing countries. Its global prevalence is underscored by more serious morbidity and some mortality in the young (<5 years) and the elderly. To date, there are no licensed vaccines or approved therapeutics for HuNoV, mostly because there are limited cell culture systems and small animal models available. Recently described cell culture systems are not ideal substrates for HuNoV vaccine development because they are not clonal or only support a single strain. In this study, we show Vero cell-based replication of two pandemic GII.4 HuNoV strains and one GII.3 strain and confirm exosome-mediated HuNoV infection in Vero cells. Lastly, we show that trypsin addition to virus cultures or disruption of Vero cell host genes can modestly increase HuNoV replication. These data provide support for Vero cells as a cell culture model for HuNoV.

show abstract

Section: Introductionmentioning

confidence: 99%

Vero Cells as a Mammalian Cell Substrate for Human Norovirus

Todd

Tripp

2020

Viruses

View full text Add to dashboard Cite

show abstract

“…HuNoVs transmit through the fecal–oral route upon ingestion of the encapsidated virions. Following a 24–48 h incubation period, HuNoVs cause symptomatic diarrhea and vomiting for the next 12–60 h [20,21,22]. The infection is self-limiting within a few days, but the virus continues to be shed in the feces for the next few weeks in immunocompetent patients [23,24,25,26].…”

Section: Introductionmentioning

confidence: 99%

Human Norovirus: Experimental Models of Infection

Todd

Tripp

2019

Viruses

View full text Add to dashboard Cite

Human noroviruses (HuNoVs) are a leading cause of acute gastroenteritis worldwide. HuNoV infections lead to substantial societal and economic burdens. There are currently no licensed vaccines or therapeutics for the prevention or treatment of HuNoVs. A lack of well-characterized in vitro and in vivo infection models has limited the development of HuNoV countermeasures. Experimental infection of human volunteers and the use of related viruses such as murine NoV have provided helpful insights into HuNoV biology and vaccine and therapeutic development. There remains a need for robust animal models and reverse genetic systems to further HuNoV research. This review summarizes available HuNoV animal models and reverse genetic systems, while providing insight into their usefulness for vaccine and therapeutic development.

show abstract

“…NoV disease is characterized by a short duration of symptoms (3), which can be severe, especially for people in high-risk groups, such as young children, the elderly, or immunocompromised patients. There is currently no vaccine available to prevent NoV infection.…”

mentioning

confidence: 99%

Genotype Considerations for Virus-Like Particle-Based Bivalent Norovirus Vaccine Composition

Malm

Tamminen

Lappalainen

et al. 2015

Clin Vaccine Immunol

View full text Add to dashboard Cite

Norovirus (NoV) genogroup I (GI) and GII are responsible for most human infections with NoV. Because of the high genetic variability of NoV, natural infection does not induce sufficient protective immunity to different genotypes or to variants of the same genotype and there is little or no cross-protection against different genogroups. NoV-derived virus-like particles (VLPs) are promising vaccine candidates that induce high levels of NoV-specific humoral and cellular immune responses. It is believed that a bivalent NoV vaccine consisting of a representative VLP from GI and GII is a minimum requirement for an effective vaccine. Here, we compared the abilities of monovalent immunizations with NoV GI.1-2001, GI.3-2002, GII.4-1999, and GII.4-2010 New Orleans VLPs to induce NoV type-specific and cross-reactive immune responses and protective blocking antibody responses in BALB/c mice. All of the VLPs induced comparable levels of type-specific serum IgG antibodies, as well as blocking antibodies to the VLPs used for immunization. However, the abilities of different VLP genotypes to induce cross-reactive IgG and cross-blocking antibodies varied remarkably. Our results confirm previous findings of a lack of cross-protective immune responses between GI and GII NoVs. These data support the rationale for including NoV GI.3 and GII.4-1999 VLPs in the bivalent vaccine formulation, which could be sufficient to induce protective immune responses across NoV genotypes in the two common genogroups in humans.

show abstract

Association of host, agent and environment characteristics and the duration of incubation and symptomatic periods of norovirus gastroenteritis

Cited by 16 publications

References 32 publications

Vero Cells as a Mammalian Cell Substrate for Human Norovirus

Vero Cells as a Mammalian Cell Substrate for Human Norovirus

Human Norovirus: Experimental Models of Infection

Genotype Considerations for Virus-Like Particle-Based Bivalent Norovirus Vaccine Composition

Contact Info

Product

Resources

About